Anthropic Reveals Claude Drug Discovery Progress: 35K Antibodies Generated, Clinical Trials Targeted for 2028

Anthropic has revealed significant progress in using its AI model, Claude, for drug discovery, announcing deep partnerships with six biopharmaceutical firms and disclosing internal R&D results. Key metrics show that Claude generated approximately 35,000 antibody designs in one month, drastically improving early-stage screening efficiency. Additionally, the AI identified seven critical production issues missed by human reviewers, demonstrating its value in quality control.

Technically, Claude's application spans the entire drug development lifecycle, from molecular design and CAR-T gene sequence optimization to regulatory document review. Reports indicate a 90% reduction in document review time. Anthropic also acquired Mithril Medicine, a micro-pharma company operated independently by AI, to validate autonomous capabilities in contracts, logistics, and experiment coordination. While some sources note the emphasis on commercial narrative over reproducible methodology, cross-verification confirms projects are primarily pre-clinical, with an internal muscle atrophy program targeting human clinical trials by late 2028.

This milestone marks the evolution of LLMs from auxiliary tools to semi-autonomous 'digital scientists.' For the industry, Anthropic's efforts demonstrate AI's potential to shorten development cycles and establish benchmarks for compliance and reliability in complex biopharma processes, likely accelerating the adoption of AI-native R&D models.